open access

Vol 15, No 2 (2008)
Original articles
Published online: 2008-02-21
Submitted: 2013-01-14
Get Citation

Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients

Małgorzata Kobusiak-Prokopowicz, Beata Jołda-Mydłowska, Agnieszka Zubkiewicz, Maciej Szymczak, Andrzej Mysiak, Robert Skalik
Cardiol J 2008;15(2):162-168.

open access

Vol 15, No 2 (2008)
Original articles
Published online: 2008-02-21
Submitted: 2013-01-14

Abstract

Background: The dysfunction of vascular endothelium precedes the development of atherosclerosis in patients with arterial hypertension. Nebivolol is a very specific beta-blocker, which can be characterized by a strong endothelial vasodilatative effect. The aim of the study was the assessment of changes in concentrations of serum nitric oxide (NO), plasma von Willebrand factor (vWf) and selected parameters of electrocardiographic exercise tests after 4-week nebivolol treatment.
Methods: Twenty-one patients were included in the study, aged from 34 to 82 years with primary arterial hypertension or primary arterial hypertension and ischemic heart disease. Blood samples were taken for measurements of serum NO and plasma vWf. Electrocardiographic stress tests were also performed. Subsequently, nebivolol was administered for four weeks and the aforementioned measurements were repeated.
Results: A significant increase in serum NO concentration was found in all the investigated patients after nebivolol treatment. A prolongation of exercise time, increase in metabolic equivalent and decrease in double product were also noted in patients after nebivolol treatment.
Conclusions: Nebivolol treatment improves parameters of electrocardiographic exercise test in patients with arterial hypertension. The improvement of the parameters of the exercise test was not observed in those patients who showed no significant increase in serum NO concentration following nebivolol treatment. (Cardiol J 2008; 15: 162-168)

Abstract

Background: The dysfunction of vascular endothelium precedes the development of atherosclerosis in patients with arterial hypertension. Nebivolol is a very specific beta-blocker, which can be characterized by a strong endothelial vasodilatative effect. The aim of the study was the assessment of changes in concentrations of serum nitric oxide (NO), plasma von Willebrand factor (vWf) and selected parameters of electrocardiographic exercise tests after 4-week nebivolol treatment.
Methods: Twenty-one patients were included in the study, aged from 34 to 82 years with primary arterial hypertension or primary arterial hypertension and ischemic heart disease. Blood samples were taken for measurements of serum NO and plasma vWf. Electrocardiographic stress tests were also performed. Subsequently, nebivolol was administered for four weeks and the aforementioned measurements were repeated.
Results: A significant increase in serum NO concentration was found in all the investigated patients after nebivolol treatment. A prolongation of exercise time, increase in metabolic equivalent and decrease in double product were also noted in patients after nebivolol treatment.
Conclusions: Nebivolol treatment improves parameters of electrocardiographic exercise test in patients with arterial hypertension. The improvement of the parameters of the exercise test was not observed in those patients who showed no significant increase in serum NO concentration following nebivolol treatment. (Cardiol J 2008; 15: 162-168)
Get Citation

Keywords

nebivolol; nitric oxide; von Willebrand factor; arterial hypertension; ischemic heart disease

About this article
Title

Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients

Journal

Cardiology Journal

Issue

Vol 15, No 2 (2008)

Pages

162-168

Published online

2008-02-21

Bibliographic record

Cardiol J 2008;15(2):162-168.

Keywords

nebivolol
nitric oxide
von Willebrand factor
arterial hypertension
ischemic heart disease

Authors

Małgorzata Kobusiak-Prokopowicz
Beata Jołda-Mydłowska
Agnieszka Zubkiewicz
Maciej Szymczak
Andrzej Mysiak
Robert Skalik

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl